Disease relevance of Sertoli-Leydig Cell Tumor

• In human epithelial ovarian cancers and an arrhenoblastoma, analogs D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Trp-NH2 (RC-95-I), D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2 (RC-121) and D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Trp-NH2 (RC-160) appeared to be the most potent in displacing labeled SS-14 [1].
• Calretinin reactivity was detected in 100% of sex cord-stromal and 90% of fibrous neoplasms, including 32 that were inhibin negative (2 granulosa cell tumors, 1 Sertoli-Leydig cell tumor, 1 thecoma, 3 fibrothecomas, 16 fibromas, 6 adenofibromas, and 3 fibrosarcomas) [2].
• In hyperandrogenism caused by a Sertoli-Leydig cell tumor, both the tumor tissue and nontumor tissue from the same ovary expressed the "testicular" form of the 17 beta-HSD [3].
• Hirsutism caused by an androgen-producing ovarian tumor. A case of arrhenoblastoma [4].
• A 16-year-old girl with virilization and elevated serum alpha-fetoprotein (AFP) levels was found to have a Sertoli-Leydig cell tumor of the ovary [5].

High impact information on Sertoli-Leydig Cell Tumor

• Norethindrone inhibition of testosterone secretion by an ovarian Sertoli-Leydig cell tumor [6].
• We conclude that norethindrone directly suppressed T production by the Sertoli-Leydig cell tumor [6].
• Testosterone secretion by cultured arrhenoblastoma cells: suppression by a luteinizing hormone-releasing hormone agonist [7].
• Ovarian Sertoli-Leydig cell tumor: a SRY gene-independent pathway of pseudomale gonadal differentiation [8].
• Although variable staining for S-100 protein was found in 5 of the 12 other SCSTs (4 Leydig cell, 6 Sertoli-Leydig cell, and 2 unclassifiable ovarian SCSTs), reactivity for smooth muscle actin was present in only 1 Sertoli-Leydig cell tumor [9].

Chemical compound and disease context of Sertoli-Leydig Cell Tumor

• OBJECTIVE: To ascertain the steroidogenic profile and location of steroidogenic enzymes in a steroid-secreting Sertoli-Leydig cell tumor of the ovary [10].
• Ovarian tissue from the same ovary as the Sertoli-Leydig cell tumor (diagnosed as theca lutein cysts on histologic examination) expressed the type 2 and 3 transcripts [3].
• A 23-year-old woman with metastatic Sertoli-Leydig cell tumor was treated with cisplatin, vinblastine, and bleomycin [11].
• The unique property of the arrhenoblastoma to convert [4-14C]17alpha-hydroxyprogesterone to [4-14C]11-deoxycortisol (Reichstein's compound S) suggests an adrenal origin of the tumour which may explain its limited capacity to aromatize testosterone [12].
• The present data suggest that: 1) androblastomas have a biosynthetic capacity for androgen, estrogen, or both in which both the delta 5 and delta 4 pathways are involved, and 2) little correlation exists between the endocrine function and cellular composition of the tumors or their degree of differentiation [13].

Biological context of Sertoli-Leydig Cell Tumor

• The clinical course, histology, and steroid secretion of a 59-year-old postmenopausal woman with a 4-yr history of virilizing well-differentiated Sertoli-Leydig cell tumor of the right ovary are reported [14].
• A case of virilizing ovarian Sertoli-Leydig cell tumor overexpressing the BCL2 gene and including a novel clonal chromosomal rearrangement of chromosome 18, der(5)t(5;18)(p13;q12),+6,+12, der(18)r(5;18)(p15.3p13;p11.3q12) is described [15].

Anatomical context of Sertoli-Leydig Cell Tumor

• Cytosol steroid receptor contents of 2 tubular androblastomas were determined and that was correlated with the response to hormonal (tamoxifen and medroxyprogesterone acetate) and cytotoxic agents (chlorambucil, vincristine, cisplatin and etoposide) using a new in vitro method based on ATP measurement of cultured cells [16].

Gene context of Sertoli-Leydig Cell Tumor

• A 13-year-old girl had an ovarian Sertoli-Leydig cell tumor associated with marked elevation of the serum alpha-fetoprotein level [17].
• Androblastoma and raised serum alpha-fetoprotein with familial multinodular goitre. Case report [18].
• OBJECTIVE: To evaluate the level of 17 beta-hydroxysteroid dehydrogenase (17 beta-HSD) type 1, 2, and 3 transcripts in a Sertoli-Leydig cell tumor, adjacent theca lutein ovarian tissue, and normal control ovarian stromal tissue [3].
• Relaxin-like factor expression in a human ovarian Sertoli-Leydig cell tumor [19].
• Ectopic ACTH syndrome due to bilateral ovarian androblastoma with double, gynandroblastic differentiation in one ovary [20].

Analytical, diagnostic and therapeutic context of Sertoli-Leydig Cell Tumor

• RESULTS: A 33-year-old woman with abrupt cessation of menses, progressive hirsutism, and weight gain because of a unilateral ovarian mass identified sonographically and an increased serum testosterone level underwent laparotomy, which disclosed a left ovarian Sertoli-Leydig cell tumor [21].

References